Company intelligence / Profile preview

QART Medical

Ownership: Private
Employees: ~11
Development stage: Preclinical

Overview

QART Medical has completed a multi-center clinical study of its flagship product, the Q300™, demonstrating favorable results in improving the selection process for sperm cells used in IVF/ICSI. The company is preparing to enter a commercial pilot phase following regulatory approvals and successful initial trials.

Therapeutic areas: Women's HealthMen's Health
Modalities: DeviceNon-pharmacological therapy (sperm selection technology for IVF)
Industry: Medical Imaging

Partnerships

Barzilai Medical Center (clinical trial site)Tel Aviv University/Ramot Technology Transfer Companyadditional undisclosed IVF centers participating in studies

Beyond the preview

Go deeper on QART Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QART Medical.

Explore the full profile